MY196438A - Pharmaceutical Composition for Treating Diabetes - Google Patents

Pharmaceutical Composition for Treating Diabetes

Info

Publication number
MY196438A
MY196438A MYPI2017702340A MYPI2017702340A MY196438A MY 196438 A MY196438 A MY 196438A MY PI2017702340 A MYPI2017702340 A MY PI2017702340A MY PI2017702340 A MYPI2017702340 A MY PI2017702340A MY 196438 A MY196438 A MY 196438A
Authority
MY
Malaysia
Prior art keywords
pharmaceutical composition
metformin
composition
treating diabetes
present
Prior art date
Application number
MYPI2017702340A
Inventor
Eon-Pyo Hong
Dong-Wook Kim
Hye-Suk Hong
Jin-Keon Pai
Original Assignee
Handok Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53500898&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MY196438(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Handok Inc filed Critical Handok Inc
Publication of MY196438A publication Critical patent/MY196438A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer

Abstract

The present invention relates to a pharmaceutical composition for use in the treatment of diabetes, containing metformin and teneligliptin. The pharmaceutical composition for use in the treatment of diabetes according to the present invention can cut off the contact between the teneligliptin and metformin, so that the lifespan of the composition is increased and the amount as well as the kind of impurities contained in the composition is reduced. Furthermore, the teneligliptin can be rapidly released and the sustained-release of metformin can be controlled. The present invention relates to a pharmaceutical composition for treating diabetes, containing metformin and a DPP-TV inhibitor. The pharmaceutical composition for treating diabetes according to the present invention can cut off the contact between the DPP-TV inhibitor and metformin, so that the lifespan of the composition is increased and the amount as well as the kind of impurities contained in the composition is reduced. Furthermore, the DPP-TV inhibitor can be rapidly released and the sustained-release of metformin can be controlled. [Accompanying Fig. 1]
MYPI2017702340A 2014-12-23 2015-12-22 Pharmaceutical Composition for Treating Diabetes MY196438A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020140186677A KR101526825B1 (en) 2014-12-23 2014-12-23 Pharmaceutical Compositions for The Treatment of Diabetes
PCT/KR2015/014096 WO2016105084A2 (en) 2014-12-23 2015-12-22 Pharmaceutical composition for treating diabetes

Publications (1)

Publication Number Publication Date
MY196438A true MY196438A (en) 2023-04-11

Family

ID=53500898

Family Applications (1)

Application Number Title Priority Date Filing Date
MYPI2017702340A MY196438A (en) 2014-12-23 2015-12-22 Pharmaceutical Composition for Treating Diabetes

Country Status (7)

Country Link
KR (1) KR101526825B1 (en)
CN (1) CN107205969B (en)
MY (1) MY196438A (en)
PH (1) PH12017501184A1 (en)
SG (1) SG11201705194XA (en)
TW (1) TW201628602A (en)
WO (1) WO2016105084A2 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106421794A (en) * 2016-09-27 2017-02-22 黑龙江珍宝岛药业股份有限公司 Drug compound for treating type II diabetes and preparation method thereof
MX2020002312A (en) * 2017-09-29 2020-09-17 Hanmi Pharm Ind Co Ltd Combined pharmaceutical formulation comprising dapagliflozin l-proline and metformin.
KR102500835B1 (en) * 2017-10-24 2023-02-17 한미약품 주식회사 Complex Preparations Comprising Lingliptin and Metformin as an active ingredients and preparing method thereof
TR201721824A2 (en) * 2017-12-26 2019-07-22 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi A MODIFIED EMISSION COMBINATION CONTAINING LINAGLIPTIN AND METFORMIN
CN113116842A (en) * 2019-12-31 2021-07-16 广州玻思韬控释药业有限公司 Stomach retention tablet
TW202329921A (en) * 2021-10-08 2023-08-01 南韓商賽特瑞恩股份有限公司 Pharmaceutical composition for treatment of diabetes with improved stability
CN115715768A (en) * 2022-11-24 2023-02-28 浙江昂利泰制药有限公司 Small sitagliptin-metformin sustained release tablet and preparation method thereof

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006080630A1 (en) * 2004-09-23 2006-08-03 Handok Pharmaceuticals Co., Ltd. Pharmaceutical combination preparation for oral delivery for the treatment of diabetes mellitus
KR100760430B1 (en) * 2004-12-31 2007-10-04 한미약품 주식회사 Controlled release complex formulation for oral administration of medicine for diabetes and method for the preparation thereof
KR101438234B1 (en) * 2005-06-03 2014-09-04 미쓰비시 타나베 파마 코퍼레이션 Concomitant pharmaceutical agents and use thereof
CN101365432B (en) * 2005-12-16 2011-06-22 默沙东公司 Pharmaceutical compositions of combinations of dipeptidyl peptidase-4 inhibitors with metformin
CN101168059A (en) * 2007-10-12 2008-04-30 重庆医药工业研究院有限责任公司 Stable medicinal composition containing biguanide, sulfonylurea and thiazolidinedione and preparation method thereof
CN101168060B (en) * 2007-10-12 2012-06-13 重庆医药工业研究院有限责任公司 Stable medicinal composition containing biguanide and sulfonylurea and preparation method thereof
JP2011510986A (en) * 2008-02-05 2011-04-07 メルク・シャープ・エンド・ドーム・コーポレイション Combination pharmaceutical composition of metformin and dipeptidyl peptidase-IV inhibitor
CA2752437C (en) * 2009-02-13 2017-07-11 Boehringer Ingelheim International Gmbh Antidiabetic medications
PL2590634T3 (en) * 2010-07-09 2016-10-31 Combination immediate/delayed release delivery system for short half-life pharmaceuticals including remogliflozin
UY33937A (en) * 2011-03-07 2012-09-28 Boehringer Ingelheim Int PHARMACEUTICAL COMPOSITIONS CONTAINING DPP-4 AND / OR SGLT-2 AND METFORMIN INHIBITORS
US9555001B2 (en) * 2012-03-07 2017-01-31 Boehringer Ingelheim International Gmbh Pharmaceutical composition and uses thereof
KR101409330B1 (en) * 2012-05-11 2014-06-18 안국약품 주식회사 Sustained-Release combination preparations for the treatment of diabetes mellitus having enhanced compliance and preparation method thereof
KR20140013436A (en) * 2012-07-24 2014-02-05 한미약품 주식회사 Composite formulation for oral administration comprising metformin and rosuvastatin
CN103285398B (en) * 2013-06-28 2015-07-22 青岛黄海制药有限责任公司 Compound preparation containing DPP-IV (dipeptidyl peptidase-IV) inhibitor and type-II diabetes medicine and preparation method thereof

Also Published As

Publication number Publication date
SG11201705194XA (en) 2017-07-28
PH12017501184B1 (en) 2017-12-18
PH12017501184A1 (en) 2017-12-18
TW201628602A (en) 2016-08-16
CN107205969A (en) 2017-09-26
KR101526825B1 (en) 2015-06-08
WO2016105084A3 (en) 2016-09-09
WO2016105084A2 (en) 2016-06-30
CN107205969B (en) 2020-06-30

Similar Documents

Publication Publication Date Title
MY196438A (en) Pharmaceutical Composition for Treating Diabetes
PH12017502297A1 (en) Antibacterial compounds
CR20160582A (en) COMPOSITION TO TREAT DIABETES, CONTAINING A PROLONGED ACTION INSULIN ANALOG AND A PROLONGED ACTION INSULINOTROPIC PEPTIDE CONJUGATE
EP4282479A3 (en) Use of pridopidine to treat depression or anxiety
PH12015502075A1 (en) Treatment of cataplexy
MX2018002962A (en) Compounds for the treatment of diseases linked to mitochondrial reactive oxygen species (ros) production.
EA033325B1 (en) Bromodomain inhibitors
MX2015009444A (en) Novel traps in the treatment of macular degeneration.
PH12016500140A1 (en) Heterobicycloaryl rorc2 inhibitors and methods of use thereof
MX2017005282A (en) New compounds as nik inhibitors.
MX2019001376A (en) Modified release composition of orlistat and acarbose for the treatment of obesity and related metabolic disorders.
MX2017001352A (en) Pyrrolidinone derivatives as metap-2 inhibitors.
PH12016501096A1 (en) SEROTONIN-NOREPINEPHRINE REUPTAKE INHIBITORS (SNRIs) AND SIGMA RECEPTOR LIGANDS COMBINATIONS
NZ726581A (en) Composition for preventing or treating dental erosion
MX359029B (en) Method of treatment of hypoxia inducible factor (hif)-related conditions.
UA115128C2 (en) Seed dressing for controlling phytopathogenic fungi
PH12018550008A1 (en) Selected amide of y-hydroxybutyric acid and uses thereof in the treatment of alcohol misuse
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
PH12017501897A1 (en) 2-thiopyrimidinones
MX2017003020A (en) Dipeptidyl ketoamide compounds and their use for the treatment and/or prevention of fat accumulation.
MX2019007067A (en) Azepane inhibitors of menin-mll interaction.
GEP20207145B (en) Combination of trazodone and gabapentin for the treatmen
MX2015017136A (en) Composition for the oral administration of magnesium, in association with a composition for treating type 2 diabetes or the complications thereof.
MY189542A (en) A process for preparing compositions for an amalgam
IN2013MU01224A (en)